Improve Your Rank!
Top Of The News: Friday, July 30

Sea snail saliva may become new treatment for most severe pain

Scientists have developed a new version of a medication, first isolated from the saliva of sea snails, that could be taken in pill form to relieve the most severe forms of pain as effectively as morphine but without risking addiction.

Read More | 0 Comments

Study examines effects of binge drinking on prospective memory in teenagers

Academics at Northumbria University have demonstrated a link between teenage binge drinking and damage to prospective memory.

Read More | 0 Comments

Spinal anesthesia has lowest risk of infections

Patients who undergo epidural or spinal anesthesia instead of general anesthesia have lesser chances of developing infections at the sites of total hip or knee replacements , reported a new study conducted in Taiwan. The study said while the risk of infection is small, the potential for problems is significant.

Read More | 0 Comments

Genedata releases patent analysis software jointly developed with DSM

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced the release of PatentExplorer, an interdisciplinary software tool for assessing the patent situation of novel biomolecules and targets.

Read More | 0 Comments

The Healing Effects of Forests

"Many people," says Dr. Eeva Karjalainen, of the Finnish Forest Research Institute, Metla, "feel relaxed and good when they are out in nature. But not many of us know that there is also scientific evidence about the healing effects of nature."

Read More | 0 Comments

Hip hope from stem cell technique

US researchers have developed a promising new technique that might one day enable doctors to regrow broken or diseased joints in patients.

Read More | 0 Comments

SAR Trial For BDP HFA Nasal Aerosol Met Objectives: Teva Respiratory

Teva Respiratory, a US-based respiratory subsidiary of Teva Pharmaceutical, has said that its hydrofluoroalkane (HFA) nasal aerosol Phase III seasonal allergic rhinitis (SAR) trial met both the primary and secondary endpoints which showed clinical efficacy in patients with SAR versus placebo.

Read More | 0 Comments

Abraxis BioScience and Specialised Therapeutics Announce Approval to Market ABRAXANE for Metastatic Breast Cancer in New Zealand

Abraxis BioScience granted exclusive marketing rights to Specialised Therapeutics for ABRAXANE in New Zealand. Specialised Therapeutics will commence distribution upon receiving reimbursement approval of ABRAXANE from the New Zealand pharmaceutical reimbursement authority, Pharmac.

Read More | 0 Comments

Devax Receives CE Mark for the AXXESSâ„¢ Drug Eluting Bifurcation Stent

Devax, Inc. announced today the company received CE (Conformité Européenne) Mark for its AXXESS™ Biolimus A9® Eluting Coronary Bifurcation Stent System (AXXESS System), allowing the company to initiate sales in the European Union and other countries that recognize the CE Mark.

Read More | 0 Comments

The mystery of healthy fat people

Why some obese people go on to become diabetic while others do not. It is common to find obese people – even morbidly obese people – who are healthier than their condition would normally allow.

Read More | 0 Comments

Scientists Tap Into Antarctic Octopus Venom

Researchers have collected venom from octopuses in Antarctica for the first time, significantly advancing our understanding of the properties of venom as a potential resource for drug development.

Read More | 0 Comments

Anturol Gel Met Phase 3 Study Primary Endpoint: Antares Pharma

Antares Pharma has said that its Anturol gel met its primary endpoint of reduction in urinary incontinence episodes for both doses studied (56mg daily or 84mg daily) in a Phase 3 study evaluating patients with overactive bladder (OAB).

Read More | 0 Comments

Stellar Pharmaceuticals Issued Uracyst(R) Patents in the United States and China

Stellar Pharmaceuticals Inc.a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, announced today that it has now been issued patents ("the patents") that are central to one of its lead products, Uracyst(R)

Read More | 0 Comments

Merck KGaA: FDA Grants Priority Review to Cladribine Tablets for the Treatment of Relapsing Forms of Multiple Sclerosis

Merck KGaA announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Cladribine Tablets as a therapy for relapsing forms of multiple sclerosis (MS).

Read More | 0 Comments

Merck KGaA: FDA Grants Priority Review to Cladribine Tablets for the Treatment of Relapsing Forms of Multiple Sclerosis

Merck KGaA announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Cladribine Tablets as a therapy for relapsing forms of multiple sclerosis (MS).

Read More | 0 Comments

Drinking alcohol can 'reduce severity' of arthritis

Drinking alcohol can not only ease the symptoms of rheumatoid arthritis it appears to reduce disease severity too, research suggests.

Read More | 0 Comments

New molecular marker could predict if breast cancer patients need chemotherapy

A new predictive marker which could help doctors to decide whether breast cancer patients would benefit from chemotherapy has been identified by a team of scientists.

Read More | 0 Comments

UPDATE 2-Spain approves GW, Almirall cannabis drug for MS

GW Pharmaceuticals Plc's cannabis-derived medicine Sativex has been approved in its second European market, Spain, as an add-on therapy for treating spasticity in patients with multiple sclerosis (MS).

Read More | 0 Comments

Illumina Gives Researchers Access to Large-Scale Whole Human Genome Sequencing

Illumina has established a new network initiative designed to link scientists looking to undertake large-scale whole human genome sequencing projects with the establishments that can carry them out.

Read More | 0 Comments

New Interactive Videos at Permanent Exhibit "Dr. Kitanomaru's Bio Pharmaceutical Laboratory" at the Science Museum

 Since July 2006, Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku, Tokyo; President: Osamu Nagayama (hereafter, “Chugai”)] has shown videos with easy-to-understand explanations on medicine, biotechnology, and cancer at the permanent exhibit "Dr. Kitanomaru's Bio Pharmaceutical Laboratory" at the Science Museum (Chiyoda-ku, Tokyo).

Read More | 0 Comments

About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.